LENZ
LENZ Therapeutics, Inc. NASDAQ Listed Mar 22, 2024$6.15
-3.00%
vs $6.34
Mkt Cap $177.2M
52w Low $6.15
0.0% of range
52w High $49.05
50d MA $8.24
200d MA $20.05
P/E (TTM)
-2.2x
EV/EBITDA
—
P/B
0.6x
Debt/Equity
0.0x
ROE
-28.9%
P/FCF
-2.5x
RSI (14)
19.70
ATR (14)
$0.43
Beta
2.29
50d MA
$8.24
200d MA
$20.05
Avg Volume
750.6K
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
CIK (SEC)
Phone
(858) 925-7000
445 Marine View Avenue · Solana Beach, CA 92014 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.91 | -1.16 | -27.5% | 9.03 | +1.8% | +0.4% | -1.4% | -6.0% | -1.3% | +10.4% | — |
| Nov 5, 2025 | AMC | -0.67 | -0.59 | +11.9% | 21.47 | +3.0% | +6.9% | +0.0% | +1.0% | +14.1% | -3.6% | — |
| Jul 30, 2025 | AMC | -0.58 | -0.53 | +8.6% | 30.76 | -0.7% | -3.2% | +0.6% | -2.1% | +3.9% | -1.0% | — |
| May 7, 2025 | AMC | -0.55 | -0.53 | +3.6% | 25.34 | +0.0% | +2.1% | +1.8% | +11.5% | -1.4% | -4.6% | — |
| Mar 19, 2025 | AMC | -0.42 | -0.46 | -9.5% | 25.52 | +8.0% | +3.1% | +0.7% | +0.6% | -0.9% | -1.3% | — |
| Nov 6, 2024 | AMC | -0.47 | -0.38 | +19.1% | 32.23 | -0.7% | +0.9% | +7.8% | +1.9% | +4.2% | -2.4% | — |
| Aug 14, 2024 | AMC | -0.49 | -0.40 | +18.4% | 23.50 | +1.1% | -3.8% | +0.7% | -0.2% | -0.9% | -0.1% | — |
| May 8, 2024 | AMC | -0.84 | -3.53 | -320.2% | 16.18 | -1.6% | -4.8% | +2.1% | +1.1% | -1.2% | +0.8% | — |
| Feb 27, 2024 | AMC | -0.13 | -0.40 | -207.7% | 14.96 | +2.5% | +3.7% | +3.4% | +0.0% | -2.1% | -2.7% | — |
| Nov 13, 2023 | AMC | -0.25 | -0.19 | +24.0% | 10.89 | +2.1% | +1.3% | -3.4% | +0.2% | +3.4% | +0.8% | — |
| Jun 29, 2023 | AMC | -6.79 | -6.82 | -0.5% | 12.26 | +0.7% | +0.4% | +1.9% | -0.7% | +1.8% | +2.3% | — |
| Mar 30, 2023 | AMC | -2.41 | -3.00 | -24.5% | 11.41 | +0.4% | +1.7% | +3.2% | -1.9% | +0.8% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12 | Piper Sandler | Downgrade | Overweight → Neutral | $12 | $9.99 | $7.68 | -23.1% | -20.8% | +1.8% | -9.4% | +0.7% | -6.0% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.13 | $10.12 | -0.1% | -2.6% | +1.2% | -8.4% | +2.5% | +4.1% |
| Mar 26 | Citigroup | Maintains | Buy → Buy | — | $9.07 | $8.91 | -1.8% | -1.4% | -6.0% | -1.3% | +10.4% | +2.2% |
| Mar 25 | BofA Securities | Maintains | Buy → Buy | — | $9.03 | $9.19 | +1.8% | +0.4% | -1.4% | -6.0% | -1.3% | +10.4% |
| Oct 20 | Raymond James | Maintains | Outperform → Outperform | — | $38.26 | $39.17 | +2.4% | -5.1% | -7.6% | -2.6% | -4.0% | +1.9% |
| Oct 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.25 | $46.75 | +1.1% | -16.1% | -0.5% | +0.5% | +7.9% | -3.3% |
| Aug 1 | Citigroup | Maintains | Buy → Buy | — | $29.77 | $30.01 | +0.8% | +0.6% | -2.1% | +3.9% | -1.0% | +6.5% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.77 | $30.01 | +0.8% | +0.6% | -2.1% | +3.9% | -1.0% | +6.5% |
| Jul 31 | Citigroup | Maintains | Buy → Buy | — | $30.76 | $30.55 | -0.7% | -3.2% | +0.6% | -2.1% | +3.9% | -1.0% |
| Jul 31 | Raymond James | Maintains | Outperform → Outperform | — | $30.76 | $30.55 | -0.7% | -3.2% | +0.6% | -2.1% | +3.9% | -1.0% |
| Jul 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.62 | $33.35 | +5.5% | -0.3% | +0.5% | -2.9% | -3.2% | +0.6% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.34 | $25.34 | +0.0% | +2.1% | +1.8% | +11.5% | -1.4% | -4.6% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.89 | $23.35 | -2.3% | -3.5% | +3.3% | +1.2% | +7.0% | +4.5% |
| Apr 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $20.26 | $21.29 | +5.1% | +14.7% | +2.8% | -3.5% | +3.3% | +1.2% |
| Mar 20 | Citigroup | Maintains | Buy → Buy | — | $25.52 | $27.57 | +8.0% | +3.1% | +0.7% | +0.6% | -0.9% | -1.3% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.23 | $32.00 | -0.7% | +0.9% | +7.8% | +1.9% | +4.2% | -2.4% |
| Aug 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.50 | $23.75 | +1.1% | -3.8% | +0.7% | -0.2% | -0.9% | -0.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.50 | $23.75 | +1.1% | -3.8% | +0.7% | -0.2% | -0.9% | -0.1% |
No insider trades available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Alpha Wave Global, Lp | 3,612,211 | $33M | — | Mar 2026 |
| 2 | Fmr Llc | 3,597,784 | $33M | Reduced | Mar 2026 |
| 3 | 72 Investment Holdings, Llc | 1,017,751 | $16M | — | Dec 2025 |
| 4 | Tang Capital Management Llc | 865,169 | $14M | Reduced | Dec 2025 |
| 5 | Aberdeen Group Plc | 1,156,161 | $11M | Added | Mar 2026 |
| 6 | Franklin Resources Inc | 1,100,148 | $10M | — | Mar 2026 |
| 7 | Vanguard Capital Management Llc | 1,041,188 | $10M | New | Mar 2026 |
| 8 | Millennium Management | 869,257 | $8M | Added | Mar 2026 |
| 9 | Morgan Stanley | 466,764 | $7M | Reduced | Dec 2025 |
| 10 | Eversource Wealth Advisors, Llc | 24,547 | $7M | Added | Mar 2026 |
| 11 | Candriam S.c.a. | 374,932 | $6M | Added | Dec 2025 |
| 12 | Bank Of America Corp /de/ | 547,534 | $5M | Added | Mar 2026 |
| 13 | Blue Owl Capital Holdings Lp | 506,722 | $5M | Added | Mar 2026 |
| 14 | Two Sigma Investments, Lp | 500,997 | $5M | Added | Mar 2026 |
| 15 | Primecap Management Co/ca/ | 472,200 | $4M | Added | Mar 2026 |
| 16 | Alyeska Investment Group, L.p. | 463,495 | $4M | — | Mar 2026 |
| 17 | Northern Trust Corp | 185,624 | $2M | Added | Mar 2026 |
| 18 | Marshall Wace, Llp | 160,264 | $1M | Added | Mar 2026 |
| 19 | Y-Intercept (Hong Kong) Ltd | 158,715 | $1M | Added | Mar 2026 |
| 20 | Ubs Group Ag | 156,989 | $1M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$177.2M
Enterprise Value
-$114.8M
P/E (TTM)
-2.16x
Forward P/E
—
PEG Ratio
-0.26x
P/B
0.62x
P/S
9.28x
P/FCF
-2.53x
EV/EBITDA
—
Shares Out
28.8M
Financials (TTM)
Revenue
$19.1M
Net Income
-$82.1M
EBITDA
-$91.1M
Free Cash Flow
-$70.0M
Op Cash Flow
-$69.2M
EPS Basic
$-2.85
EPS Diluted
$-2.85
EPS Forward
$-3.93
Gross Margin
97.8%
Op Margin
-477.5%
Net Margin
-430.2%
Balance Sheet
Total Assets
$305.9M
Total Liab.
$21.5M
Total Equity
$284.3M
Cash
$292.3M
LT Debt
$350K
Book Value/Sh
$9.87
Debt/Equity
0.00x
Current Ratio
13.80
Quick Ratio
13.80
Returns & Growth
ROE
-28.9%
ROA
-26.9%
ROIC
-32.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-21.8%
Price Returns
2W
+6.7%
1M
-13.4%
3M
-42.3%
6M
-74.5%
12M
-73.4%
Technicals
52W High
$49.05
52W Low
$6.15
50d MA
$8.24
200d MA
$20.05
RSI (14)
19.70
ATR (14)
$0.43
Beta
2.29
Avg Volume
751K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$51.67
High
$67.00
Low
$32.00
Median
$56.00
Data updated apr 25, 2026 6:51pm
· Source: financialmodelingprep.com